skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), and alleged drug for the treatment of Alzheimer's disease

Journal Article · · Life Sci.; (United States)

In a recent study the authors have documented the acetylcholinesterase and outward K+-current inhibiting activity of 9-amino-1,2,3,4-tetrahydroacridine (THA), a drug reportedly active in the treatment of Alzheimer patients. In the present study they have investigated the effects of THA on the uptake and release of radiolabeled NA, DA and 5-HT. THA concentration-dependently inhibited the uptake of these monoamines with IC-50 values of approximately 1, 7 and 2 ..mu..M respectively. Release studies of these radiolabeled monoamines from control and reserpine pretreated tissue revealed that the THA-induced uptake inhibition does not occur at the level of the axonal membrane but at the level of the monoaminergic storage granules. In addition the affinity of THA for alpha-1, alpha-2 and beta-adrenoceptors, for D-2 dopamine, S-la and S-2 serotonin and for muscarinic receptors was investigated. It appeared that in concentrations up to 1 ..mu..M THA did not display any affinity towards these receptors. It is concluded from these experiments that the effects of THA on monoaminergic neurotransmission might contribute to the alleged therapeutic action of THA in Alzheimer's disease. 17 references, 3 figures, 1 table.

Research Organization:
Free Univ., Amsterdam, Netherlands
OSTI ID:
5471576
Journal Information:
Life Sci.; (United States), Vol. 42:9
Country of Publication:
United States
Language:
English